Dear Ms. Lowry:

Please refer to your Supplemental New Drug Application (sNDA) dated March 17, 2009, received March 18, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Furadantin (nitrofurantoin) Oral Suspension, 25mg/5mL.

This “Changes Being Effected” supplemental new drug application provides for labeling text changes to the 230 mL carton labeling.

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

**CARTON AND IMMEDIATE CONTAINER LABELS**

Submit final printed carton and container labels that are identical to the enclosed carton and immediate container labels submitted on March 17, 2009, as soon as they are available, but no more than 30 days after they are printed.

**LETTERS TO HEALTH CARE PROFESSIONALS**

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:
REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call J. Christopher Davi, MS, Senior Regulatory Project Manager, at (301) 796-0702.

Sincerely,

{See appended electronic signature page}

Katherine A. Laessig, MD
Deputy Director
Division of Anti-Infective and Ophthalmology Products
Office of Antimicrobial Products
Center for Drug Evaluation and Research

ENCLOSURE: Carton and Container Labeling Submitted on March 17, 2009
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

KATHERINE A LAESSIG
10/27/2010